Merck acquires Silence Therapeutics
Biotech, siRNA therapeutics · London, United Kingdomacquired byMerckadvised by
- Sell-side
- Morgan Stanley(M&A)Cooley(Recht)
- Buy-side
- A&O Shearman(Recht)
- Other
- Centerview Partners
Merck acquires the British biotech company Silence Therapeutics and values it at around US$1.1bn. Closing is planned for the first quarter of 2027.
- Buyer
- Merck
- Target
- Silence Therapeutics, London
- Type
- Strategic
- Sector
- Healthcare & Medtech
- Country
- United Kingdom
- First reported
- 19/10/2026
- Sell-side
- Morgan Stanley, Cooley, according to the source
- Buy-side
- A&O Shearman, according to the source
- Other
- Centerview Partners, according to the source
- Source
- manager-magazin.de
Deal-Radar no. 43-069 · publicly reported, without guarantee · SourcingClub was not involved in this transaction. Report an error · Method
Transactions by Merck
So far this is the only transaction by Merck published in the Deal-Radar. New deals are added every Monday.
Acquisitions abroad in Week 43/2026
All deals in October 2026Every Monday, all deals of the previous week, with source.
Information from public sources, without guarantee and without claim to completeness. No investment or legal advice. Published on 26 October 2026.